All Stories

  1. Application of Machine Learning in Drug Repurposing of a New Antiseizure Drugs Active in the PTZ Kindling Model
  2. Computer-Aided Discovery of Drugs Against Chagas Disease
  3. Tackling the issue of confined chemical space with AI-based de novo drug design and molecular optimization
  4. LIDEB's Useful Decoys (LUDe): A freely available decoy-generation tool. Benchmarking and scope
  5. An update on the novel methods for the discovery of antiseizure and antiepileptogenic medications: where are we in 2024?
  6. Clustering of small molecules: new perspectives and their impact on natural product lead discovery
  7. Clustering of Small Molecules
  8. Compartmental Pharmacokinetic Models
  9. Drug Absorption
  10. Drug Distribution
  11. Drug Excretion
  12. Drug Metabolism
  13. Garbage in, garbage out: how reliable training data improved a virtual screening approach against SARS-CoV-2 MPro
  14. Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease
  15. LIDeB Tools: A Latin American resource of freely available, open-source cheminformatics apps
  16. iRaPCA and SOMoC: Development and Validation of Web Applications for New Approaches for the Clustering of Small Molecules
  17. Drug Discovery Paradigms: Phenotypic-Based Drug Discovery
  18. Structure-Based Binding Pocket Detection and Druggability Assessment
  19. Free Drug Theory
  20. Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study
  21. Ensemble learning application to discover new trypanothione synthetase inhibitors
  22. Active and Facilitated Transport in Drug Absorption
  23. Biliary Drug Excretion
  24. Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient
  25. Central Nervous System Bioavailability
  26. Cytochrome P450
  27. Drug Absorption
  28. Drug Binding to Plasma Proteins
  29. Drug Binding to Tissue Components
  30. Drug Distribution
  31. Drug Excretion
  32. Drug Metabolism
  33. Drug Metabolism Functionalization (Phase I) Reactions
  34. Drug Metabolism Synthetic (Phase II) Reactions
  35. Enterohepatic Recycling
  36. Enzyme Induction and Drug Metabolism
  37. Factors Impacting on Drug Metabolism
  38. Free Diffusion in Drug Absorption
  39. Intestinal Perfusion Models
  40. One-Compartment Pharmacokinetic Model
  41. Organic Anion Transporters and Organic Anion Transporting Polypeptides
  42. Organic Cation Transporters
  43. Peptide Transporters
  44. Personalized Medicine and Drug Metabolism
  45. Phase 0 and Phase III Transport
  46. Real and Apparent Volumes of Distribution
  47. Renal Drug Excretion
  48. Solute Carrier (SLC) Transporters: An Overview
  49. Total Clearance and Organ Clearance
  50. Transcytosis in Drug Absorption and Distribution
  51. Unbound Brain-to-Plasma Partition Coefficient Determination
  52. pH Partition Theory
  53. pKa Determination
  54. Can drug repurposing strategies be the solution to the COVID-19 crisis?
  55. Positive Predictive Value Surfaces as a Complementary Tool to Assess the Performance of Virtual Screening Methods
  56. In Silico Drug Repositioning for Chagas Disease
  57. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
  58. Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease
  59. Quantitative structure–activity relationship models for compounds with anticonvulsant activity
  60. In Silico Modeling of FDA-Approved Drugs for Discovery of Therapies Against Neglected Diseases: A Drug Repurposing Approach
  61. Application of Machine Learning Approaches to Identify New Anticonvulsant Compounds Active in the 6 Hz Seizure Model
  62. Modern Approaches for the Discovery of Anti-Infectious Drugs for the Treatment of Neglected Diseases
  63. Drug Excretion
  64. Drug Absorption
  65. Drug Distribution
  66. Drug Metabolism
  67. Drug Transporters
  68. The Challenge of Finding New Therapies for Sleeping Sickness
  69. The application of molecular topology for ulcerative colitis drug discovery
  70. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease
  71. Computer-guided drug repurposing: Identification of trypanocidal activity of clofazimine, benidipine and saquinavir
  72. Identification of Levothyroxine Antichagasic Activity through Computer-Aided Drug Repurposing
  73. Application of Computer-Aided Drug Repurposing in the Search of New Cruzipain Inhibitors: Discovery of Amiodarone and Bromocriptine Inhibitory Effects
  74. CNS Drug Development – Lost in Translation?
  75. An Integrated Drug Development Approach Applying Topological Descriptors
  76. Synthesis of 2-Hydrazolyl-4-Thiazolidinones Based on Multicomponent Reactions and Biological Evaluation Against Trypanosoma Cruzi
  77. Prediction of drug intestinal absorption by new linear and non-linear QSPR
  78. A successful virtual screening application: prediction of anticonvulsant activity in MES test of widely used pharmaceutical and food preservatives methylparaben and propylparaben
  79. Application of descriptors based on Lipinski’s rules in the QSPR study of aqueous solubilities